X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Apretude (cabotegravir) long-acting for PrEP is an integrase strand transfer inhibitor (INSTI), which is indicated for the treatment of sexually acquired HIV-1 infection.
Lead Product(s): Cabotegravir
Therapeutic Area: Infections and Infectious Diseases Product Name: Apretude
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: GSK
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 19, 2023
Details:
Ojjaara (momelotinib) has a novel mechanism of action, with inhibitory ability along three key signalling pathways: Janus kinase (JAK) 1, JAK2, and activin A receptor, type I (ACVR1), which is approved for myelofibrosis and contributes to anaemia.
Lead Product(s): Momelotinib
Therapeutic Area: Oncology Product Name: Ojjaara
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 15, 2023
Details:
GS-0387 (momelotinib) has a novel mechanism of action, with inhibitory ability along three key signalling pathways: Janus kinase (JAK) 1, JAK2, and activin A receptor, type I (ACVR1), which is investicated for myelofibrosis and contributes to anaemia.
Lead Product(s): Momelotinib
Therapeutic Area: Oncology Product Name: GS-0387
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 11, 2023
Details:
Nucala (mepolizumab) is the first-in-class monoclonal antibody to target IL-5. It is believed to work by preventing IL-5 from binding to its receptor on the surface of eosinophils, reducing blood eosinophils and maintaining them within normal levels.
Lead Product(s): Mepolizumab
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: Nucala
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 01, 2023
Details:
Shingrix (recombinant zoster vaccine – RZV) is a non-live, recombinant sub-unit vaccine indicated for the prevention of herpes zoster (HZ) in adults aged 50 and over.
Lead Product(s): Guaifenesin,Adjuvanted Recombinant Zoster Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Shingrix
Highest Development Status: Phase IVProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 23, 2023
Details:
GSK101 (IDE705), a small molecule inhibitor of Pol Theta Helicase, in combination with niraparib, the GSK small molecule inhibitor of PARP for the treatment of patients having tumors with BRCA or other homologous recombination mutations.
Lead Product(s): IDE705,Niraparib Tosylate
Therapeutic Area: Oncology Product Name: GSK101
Highest Development Status: IND EnablingProduct Type: Small molecule
Recipient: Ideaya Biosciences
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 21, 2023
Details:
The monovalent candidate, CV0601, encodes the spike protein of the omicron BA.4-5 variant and is being developed in collaboration with GSK
Lead Product(s): CV0601
Therapeutic Area: Infections and Infectious Diseases Product Name: CV0601
Highest Development Status: Phase IIProduct Type: Vaccine
Recipient: CureVac
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 01, 2023
Details:
JEMPERLI (dostarlimab-gxly) is a programmed death receptor-1 (PD-1)-blocking antibody that binds to the PD-1 receptor and blocks its interaction with the PD-1 ligands PD-L1 and PD-L2.
Lead Product(s): Dostarlimab-gxly,Carboplatin,Paclitaxel
Therapeutic Area: Oncology Product Name: Jemperli
Highest Development Status: ApprovedProduct Type: Large molecule
Recipient: AnaptysBio
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 31, 2023
Details:
CAB LA (cabotegravir) long-acting for PrEP is an integrase strand transfer inhibitor (INSTI). INSTIs, like cabotegravir extended-release injectable suspension, inhibit HIV replication by preventing the viral DNA from integrating into the genetic material of human immune cells.
Lead Product(s): Cabotegravir
Therapeutic Area: Infections and Infectious Diseases Product Name: CAB LA
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 24, 2023
Details:
The collaboration aims to advance the discovery and development of Elsie’s innovative oligonucleotide discovery platform for finding novel oligonucleotides by combining GSK's extensive expertise in DNA encoded library technologies with Elsie's drug discovery platform.
Lead Product(s): Oligonucleotide Drug
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Recipient: Elsie Biotechnologies
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 10, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
